Diabetology for primary health care – the use of metformin in the treatment of prediabetes, primary prevention and secondary prevention in type 2 diabetes Review article
Article Sidebar
Published:
Dec 31, 2021
Keywords:
prediabetes, insulin resistance, metformin, primary prevention, secondary prevention, guidelines
Main Article Content
Abstract
The 2021 guidelines on the management of diabetes by the Polish Diabetes Association introduce the new criterion for the diagnosis of diabetes – percentage of glycated hemoglobin HbA1c > 6.5%. This is important, especially now, during the COVID-19 epidemic, for patients with diagnosed pre-diabetes who are already using metformin, as it allows to release the need for an oral glucose tolerance test. The article describes the principles of using metformin in the prevention of type 2 diabetes.
Article Details
How to Cite
Dzida , G. (2021). Diabetology for primary health care – the use of metformin in the treatment of prediabetes, primary prevention and secondary prevention in type 2 diabetes. Medycyna Faktow (J EBM), 14(4(53), 346-348. https://doi.org/10.24292/01.MF.0421.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2021. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetol Prakt. 2021; 7(1): 1-121.
2. ADA. Standards of Medical Care in Diabetes 2021. Diabetes Care. 2021; 44(suppl 1).
3. Wagner R, Heni M, Tabak A et al. Pathophysiology based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021; 27: 49-57. http://doi.org/10.1038/s41591-020-1116-9.
4. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002; 346: 393-403.
2. ADA. Standards of Medical Care in Diabetes 2021. Diabetes Care. 2021; 44(suppl 1).
3. Wagner R, Heni M, Tabak A et al. Pathophysiology based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021; 27: 49-57. http://doi.org/10.1038/s41591-020-1116-9.
4. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002; 346: 393-403.